PAVmed- Warrants (29/01/2022) Overview
Latest ROE for PAVmed- Warrants (29/01/2022): -67.37% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-67.37%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for PAVMW is -67.37%. That is below the Healthcare sector average of 22.76%. Investors often review this figure alongside PAVmed- Warrants (29/01/2022)'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PAVMW currently prints -67.37% for ROE, while the sector average sits near 22.76%. That is roughly 395.9% below the sector mean. Large gaps often invite a closer look at PAVmed- Warrants (29/01/2022)'s growth, margins, and balance sheet.
Return on Equity shows how effectively PAVmed- Warrants (29/01/2022) converts resources into returns. At -67.37%, PAVMW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PAVMW's ROE (-67.37%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack PAVmed- Warrants (29/01/2022)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
